Psoriāze pacientiem ar onkoloģiskām saslimšanām

Vanda Bondare-Ansberga; Ilona Hartmane

Abstract

According to the literature, psoriasis patients have an increased risk of malignancy, especially in patients with severe psoriasis. Chronic inflammation is believed to be one of the risk factors linking psoriasis to malignancy.
Malignancy is most often an exclusion criterion in randomized clinical trials, so data from randomized trials are not available for this patient group and clinicians can obtain information from observations and real-world data studies.
Current data from population studies show that treatment with IL-17 and IL-23 inhibitors is associated with a reduced risk of several malignancies.
EuroGuiDerm Clinical Guidelines allow the use of biologics in psoriasis patients with malignant tumors. However, due to the lack of rigorous research data on the use of biological therapy in cancer patients, a decision on the use of therapy should be made on case-by-case basis, discussing with the patient and considering recommendations from the treating oncologist.

Translated title of the contribution	Psoriasis in patients with oncological diseases
Original language	Latvian
Pages	41
Number of pages	1
Publication status	Published - 9 Nov 2024
Externally published	Yes
Event	LDVA 19TH Congress with International Participation “Latest Achievements in Dermatology, Venereology, Oncology and Aesthetics” - "Islande" hotel, Riga, Latvia Duration: 8 Nov 2024 → 9 Nov 2024 Conference number: 19 https://ldva2024riga.org/en/ldva2024/

Congress

Congress	LDVA 19TH Congress with International Participation “Latest Achievements in Dermatology, Venereology, Oncology and Aesthetics”
Abbreviated title	LDVA
Country/Territory	Latvia
City	Riga
Period	8/11/24 → 9/11/24
Internet address	https://ldva2024riga.org/en/ldva2024/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords*

Psoriasis

Field of Science*

3.2 Clinical medicine

Publication Type*

3.4. Other publications in conference proceedings (including local)

Cite this

@conference{2a496829de8948af84cdcb60709cf9ef,

title = "Psoriāze pacientiem ar onkoloģiskām saslim{\v s}anām",

abstract = "According to the literature, psoriasis patients have an increased risk of malignancy, especially in patients with severe psoriasis. Chronic inflammation is believed to be one of the risk factors linking psoriasis to malignancy. Malignancy is most often an exclusion criterion in randomized clinical trials, so data from randomized trials are not available for this patient group and clinicians can obtain information from observations and real-world data studies. Current data from population studies show that treatment with IL-17 and IL-23 inhibitors is associated with a reduced risk of several malignancies. EuroGuiDerm Clinical Guidelines allow the use of biologics in psoriasis patients with malignant tumors. However, due to the lack of rigorous research data on the use of biological therapy in cancer patients, a decision on the use of therapy should be made on case-by-case basis, discussing with the patient and considering recommendations from the treating oncologist.",

keywords = "Psoriasis",

author = "Vanda Bondare-Ansberga and Ilona Hartmane",

year = "2024",

month = nov,

day = "9",

language = "Latvian",

pages = "41",

note = "LDVA 19TH Congress with International Participation {\textquotedblleft}Latest Achievements in Dermatology, Venereology, Oncology and Aesthetics{\textquotedblright} ; Conference date: 08-11-2024 Through 09-11-2024",

url = "https://ldva2024riga.org/en/ldva2024/",

}

TY - CONF

T1 - Psoriāze pacientiem ar onkoloģiskām saslimšanām

AU - Bondare-Ansberga , Vanda

AU - Hartmane, Ilona

N1 - Conference code: 19

PY - 2024/11/9

Y1 - 2024/11/9

N2 - According to the literature, psoriasis patients have an increased risk of malignancy, especially in patients with severe psoriasis. Chronic inflammation is believed to be one of the risk factors linking psoriasis to malignancy. Malignancy is most often an exclusion criterion in randomized clinical trials, so data from randomized trials are not available for this patient group and clinicians can obtain information from observations and real-world data studies. Current data from population studies show that treatment with IL-17 and IL-23 inhibitors is associated with a reduced risk of several malignancies. EuroGuiDerm Clinical Guidelines allow the use of biologics in psoriasis patients with malignant tumors. However, due to the lack of rigorous research data on the use of biological therapy in cancer patients, a decision on the use of therapy should be made on case-by-case basis, discussing with the patient and considering recommendations from the treating oncologist.

AB - According to the literature, psoriasis patients have an increased risk of malignancy, especially in patients with severe psoriasis. Chronic inflammation is believed to be one of the risk factors linking psoriasis to malignancy. Malignancy is most often an exclusion criterion in randomized clinical trials, so data from randomized trials are not available for this patient group and clinicians can obtain information from observations and real-world data studies. Current data from population studies show that treatment with IL-17 and IL-23 inhibitors is associated with a reduced risk of several malignancies. EuroGuiDerm Clinical Guidelines allow the use of biologics in psoriasis patients with malignant tumors. However, due to the lack of rigorous research data on the use of biological therapy in cancer patients, a decision on the use of therapy should be made on case-by-case basis, discussing with the patient and considering recommendations from the treating oncologist.

KW - Psoriasis

M3 - Abstract

SP - 41

T2 - LDVA 19TH Congress with International Participation “Latest Achievements in Dermatology, Venereology, Oncology and Aesthetics”

Y2 - 8 November 2024 through 9 November 2024

ER -